performing more prostatectomies such as in the US. The fact that most patients were identified clinically is reflected in their mean baseline PSA level of 13.5 ng/ml, as compared with two-thirds of newly diagnosed cases in the US, which are stage T1c, and the majority undergoing radical prostatectomy have a PSA level < 10 ng/ml. The 8 years of follow-up is inadequate to clearly define progression and survival. For example, 35 as compared with 54 patients developed metastases in the surgery and observation arms, respectively. These patients are incurable and will further widen the survival difference. Furthermore, disease in patients without evidence of biochemical disease at 8 years is unlikely to recur, meaning that the additional number of patients presenting with metastasis in the upcoming years should not greatly increase.
Quality of life after radical prostatectomy or watchful waiting
An evaluation of symptoms and quality of life was also conducted in the comparative study of radical prostatectomy and watchful waiting in men with localized prostate cancer discussed above (Steineck et al, New Engl J Med 2002; 347: 790 -796) . In this follow-up study, information was obtained from 326/376 eligible patients (87%) on specific symptoms, symptom-induced distress, well-being and the subjective assessment of quality of life using a mailed questionnaire.
Results indicated that erectile dysfunction (80% vs 45%) and urinary leakage (49% vs 21%) were more frequent after surgery but that urinary obstruction was less common. For example, the rate of weak urinary stream post-radical prostatectomy was 28% compared with 44% in the watchful waiting group; equivalent figures for involuntary stoppages during urination were 12% vs 21% and for sensation of not completely emptying the bladder 21% vs 30%. No differences between the two groups were reported for bowel function, prevalence of anxiety or depression, well-being and subjective quality of life.
It should be recognized that those on watchful waiting who progress may have a significantly decreased quality of life in their final years, perhaps eclipsing the early differences noted above.
EBRT vs EBRT plus immediate androgen suppression
Results from a randomized phase III trial comparing external beam radiotherapy (EBRT) alone and EBRT plus a luteinising hormone-releasing hormone analogue (LHRHa) in men with locally advanced prostate cancer have recently been reported by Bolla et al (Lancet 2002; 360: 103 -108) . A total of 415 men with T1 -2 tumours of WHO grade 3 or T3 -4 N0 -1 M tumours were randomly assigned to the two treatment arms; mean age was 71 y (range: 51 -80 y). Both groups had 50 Gy radiation delivered to the pelvis over a 5-week period with a prostatic boost of 20 Gy over 2 weeks. The LHRHa, goserelin, was administered subcutaneously at a dose of 3 -6 mg every 4 weeks starting on the first day of radiotherapy and continuing for 3 years. The steroidal antiandrogen, cyproterone acetate, was given at a dose of 150 mg orally for 1 month starting 1 week before the first goserelin dose. The primary endpoint of the study was clinical diseasefree survival.
Data were reported for 412 men with a median followup of 66 months, range: 1 -126). Clinical disease-free survival at 5 years was shown to be higher in patients treated with EBRT plus immediate androgen suppression than in those treated with EBRT alone; 74% vs 40% (P ¼ 0.0001). Overall survival at 5 years was also higher in the combination therapy group at 78% compared with 62% in the EBRT alone group (P ¼ 0.0002), as was 5 year specific survival: 94% vs 79% (P ¼ 0.0001).
It was concluded that immediate androgen suppression with an LHRHa administered over a 3 year period following EBRT improves disease-free and overall survival in patients with locally advanced prostate cancer.
Critical interpretation of the ASTRO failure criteria PSA has become an acceptable measure of the effectiveness of therapy for prostate cancer but the definition of failure varies according to treatment modality. The American Society for Therapeutic Radiation and Oncology (ASTRO) define biochemical failure following radiotherapy as three consecutive increases in PSA. For clinical trials, the date of failure is the midpoint between the postirradiation nadir PSA and the first of the three consecutive rises. Gretzer et al (J Urol 2002; 168: 1419 -1422) have applied this criteria to patients treated with radical prostatectomy to see how it compares to biochemical failure defined as any measurable PSA of 0.2 ng/ml or higher.
A retrospective review was conducted of 2691 men who underwent radical prostatectomy for localized prostate cancer during 1985 and 2000. Radiotherapy or hormonal therapy was not applied preoperatively or postoperatively until clinical recurrence. The following elements of the ASTRO criteria were applied:
1. Backdating the failure date to the midpoint between nadir and first PSA > 0.2 ng/ml. 2. Early censoring if only 1 or 2 increasing values were available. 3. Defining failure after three consecutive PSA increases and backdating failure time (midpoint of nadir and first PSA increase).
Using the criteria of failure as the first PSA of 0.2 ng/ml or greater, biochemical freedom from failure rates at 5, 10 and 15 years was 85, 77 and 68%, respectively. Backdating the failure date resulted in freedom from failure rates of 82, 80 and 80% at 5, 10 and 15 years, respectively. If the ASTRO criteria of three consecutive rises plus backdating was applied, then freedom from failure rates were even more pronounced at 90% for 5,10 or 15 years each. The authors of the report conclude that there was an apparent improvement in the probability of having freedom from biochemical disease at 15 years (from 68 to 90%) if the ASTRO criteria are applied to a mature series of surgically treated patients with localized prostate cancer. They note that care should be taken when interpreting outcomes from different series involving radiotherapy or surgery due to the inherent differences in defining biochemical failure.
Salvage radiotherapy following radical prostatectomy
Song et al (Urology 2002; 60: 281 -287) have reported the results from a study assessing the effectiveness of salvage radiotherapy for persistent or rising PSA after radical prostatectomy. Data on 61 patients treated over a 10 year period (1989 -1999) show that median PSA before radiotherapy was 0.8 ng/ml (range 0.1 -63 ng/ml). Mean radiation dose prescribed was 66.6 Gy and the actuarial PSA-free survival rate at 4 years was 39%. After 4 years following radiotherapy, failure was uncommon. Significant predictors of improved disease-free survival identified from a univariate analysis included:
Pre-radiotherapy PSA level < 1.0 ng/ml (P ¼ 0.001) Gleason score < 8 (P ¼ 0.003) Attaining an undetectable PSA level after prostatectomy (P ¼ 0.018).
A multivariate analysis indicated that pre-radiotherapy PSA < 1.0 ng/ml plus a Gleason score 8 were significant predictors.
These data would suggest that intermediate-term disease-free survival can be achieved with salvage radiotherapy in patients with persistent or rising PSA following radical prostatectomy. Certain patients are unlikely to benefit from radiotherapy, ie PSA > 1 ng/ml and Gleason score 8, and other therapies need to be identified for this group of patients.
Radical prostatectomy rates in the UK and Ireland
A survey on radical prostatectomy amongst 409 urologists in the UK and Ireland was conducted by means of a questionnaire during 1999/2000 (Ravichandran et al, BJU lnt 2002; 90: 420). Overall, 157 (38%) consultants were performing radical prostatectomy. Of these, 29 performed more than 20 procedures per year; 44 undertook 11 -20 and 84 carried out 10 or less procedures. Of the 252 consultants not performing this technique, 23 stated that they desired to do so. The fact that over 50% of consultants carry out 10 or less radical prostatectomies suggests the need for outcome data to assess efficacy.
Clinical significance of multifocal prostate cancers
A study by Wise et al (Urology 2002; 60: 264 -269) reports that PSA failure rates were similar to index tumours and the index plus smaller cancers, suggesting that predictive estimates only need to measure the largest carcinoma. Prostate specimens from 486 men treated by radical prostatectomy were studied. Tumour volume and percentage Gleason grade 4/5 carcinomas were recorded in 3 mm step sections. Mean tumour volume was 4.16 cc. Smaller cancer volumes averaged 0.63 cc and were highly skewed toward volumes less than 0.5 cc (234 carcinomas). In only 17% of cases was only one carcinoma present. The Cox model showed similar hazard rates of PSA failure for index (3.43) and total cancer (3.74) volumes. The hazard rate was 6.5 for the presence of any Gleason grade 4/5 carcinoma. It was also noted that the greater the number of small cancers, the smaller the size of the index cancer. The authors of the report suggest that the poor correlation between 6 or more biopsies with the index cancer in radical prostatectomy specimens may be explained by the extraordinary multiplicity of these small independent cancers.
Follow-up prostate biopsy for high grade PIN
Recent research suggests that follow-up after detection of high grade intraepithelial neoplasias (PIN) is necessary regardless of any changes in SA (Lefkowitz et al, J Urol 2002; 168: 1415 -1418). A total of 31 men with high grade PIN diagnosed in 1996 to 1997 underwent follow-up interval biopsy after 3 years, regardless of PSA or digital rectal examination findings. A minimum of 12 biopsy cores had been taken at the time of the original diagnosis. At follow-up, prostate cancer was detected in eight (25.8%) men, 11 (35.5%) had high grade PIN only and 12 (38.7%) had no disease. Mean serum PSA at diagnosis and at 3 years was 6.88 and 9.69 ng/dl, respectively (P ¼ 0.008). Overall, 48% of the men had less than a 1.0 unit rise in PSA. Univariate regression analysis indicated that change in PSA was not associated with prostate cancer detection. These data also imply that a high proportion of men with high-grade PIN will develop prostate cancer within a 3 year interval.
Vitamin E in prostate cancer prevention
New data suggest that vitamin E can induce cell cycle arrest through up-regulation of p27 in prostate cancer cell lines (Venkateswaran et al, J Urol 2002; 168: 1578 -1582 . LNCaP and PC3 cells were incubated with and without vitamin E (a-tocopherol succinate 20 mg/ml) and flow cytometry analysis conducted. Cell cycle markers were also studied following extract of total protein, immunoprecipitation with cyclin E antibody and western blot analysis. A dramatic reduction in the percentage of S phase LNCaP and PC3 cells was noted in response to incubation with vitamin E: 69% and 95%, respectively. This was accompanied by a 3-fold overexpression of p27.
It had previously been thought that the prostate cancer prevention activity of vitamin E was due to a reduction in reactive oxygen species. These new data would imply a mechanism involving cell cycle reduction.
SIU meeting, Stockholm
The following is a summary of selected abstracts from the BPH medical therapy poster session held during the 26th Congress of the Société Internationale d'Urologie (SIU) in Stockholm, 8 -12 September 2002 .
Improved sexual function with tamsulosin (Debruyne et al, abstract P-1.2.01)
A pooled analysis of three phase III clinical trials on tamsulosin indicates that the drug improves sexual function in men with BPH. A total of 1027 men were included in the 3-month placebo controlled studies with open label extensions of up to 4 years. A significant improvement in sexual functioning based on a life style questionnaire was reported by patients on tamsulosin compared with placebo. This is in contrast to the abnormal ejaculation reported by 34 (3.3%) of patients on the drug. However, only three patients discontinued therapy due to this adverse event, suggesting that patients in general are not particularly bothered by it. In real life practice, retrograde ejaculation has been reported by 0.5% of 12 484 patients.
Tamsulosin reduces the risk of AUR (Speakman et al, abstract P-1.
2.03)
Pooled open label studies involving 1031 men with lower urinary tract symptoms (LUTS)/benign prostatic obstruction indicate low rates of acute urinary retention (AUR) in men treated with tamsulosin. After 6 months of therapy, the incidence of AUR was 0.5% (4/791 patients) and at 12 months it was 1.1% (8/697 patients). The authors stated that these rates were of the same order as reported for alfuzosin in a 6 month placebo controlled study (0.4% vs 2.6% for placebo) and the 12 month incidence on finasteride (0.9% vs 2.6% for placebo) in the PROscar Long-Term Efficacy and Safety Study (PLESS). The lack of placebo controls and the short-term nature of the studies on tamsulosin were noted in the discussion of this poster.
Risk of AUR: 5a-reductase inhibitors vs a blockers (Boyle et al, abstract P-1.2.24)
A retrospective analysis was conducted of the General Practice Research Database (GPRD) (UK) on the incidence of surgery and AUR in patients with BPH treated with the 5a-reductase inhibitor finasteride or an a blocker. The cohort contained 4500 patients aged 50 y and over experiencing BPH or LUTS suggestive of BPH, who were prescribed their first treatment with a finasteride or an a blocker (alfuzosin, doxazosin, indoramin, prazosin, tamsulosin, terazosin) between 1996 and 1999. Kaplan -Meier and Cox proportional hazards analyses followed patients from the start of the first BPH treatment to a failure or censoring (applied at a record of death, de-registration from GPRD, medication switch, or 4 weeks after the end of first treatment). A failure was defined as a record of BPH-related catheterization, AUR, or surgery.
Results indicated that significantly fewer patients prescribed finasteride experienced AUR or surgery compared with those prescribed a blockers (P 0.001 at all time points (unadjusted)). Patients receiving finasteride were also at approximately half the risk of failure compared with those on a blockers (relative risk 0.50 (95% CI: 0.35, 0.73) P < 0.001 adjusted for age and year of treatment). It was noted that the difference in failure rates continued to increase beyond the first year of treatment suggesting that the greater proportion of failures with a blocker was not due to men receiving short-term a blocker treatment while on a waiting list for surgery. Results showed that symptom score increased by a median of 0.2 points per year (25 and 75th percentile, 70.35, 0.60) for men in their 40s to 0.43 points per year (70.12, 1.16) for men in their 60s. The median change in bother score was 0 (70.30, 0.29) across all ages. The correlation between longitudinal symptom score slopes and bother score slopes was 0.55 (P ¼ 0.001) overall and this was similar for different ages. These results suggest that there is a great deal of variability in the longitudinal change in severity and bother of LUTS in different individuals. While frequency and bother tracked together fairly closely within individuals, there remained some men in whom an increase in frequency of symptoms did not translate into an increase in bother, suggesting that they may adapt or come to accept their worsening symptoms with age.
Olmsted County Study: frequency and bothersomeness of LUTS
Laser prostatectomy vs TURP: 3 year follow-up
Three year follow-up data have been published on a study comparing laser prostatectomy with transurethral resection of the prostate (TURP) in men with BPH (Shingleton et al, Urology 2002; 60: 305 -308) . A total of 100 men who had failed medical therapy for BPH were randomized to treatment with TURP or laser prostatectomy. Follow-up at 1, 3, 6 and 12 months and annually thereafter was conducted and included: symptom score, peak urinary flow rate, PSA and transrectal ultrasongraphy (TRUS) volume. Mean symptom score decreased from 22.0 to 9.9 points at 36 months follow-up for laser-treated patients and from 21.2 to 7.7 points for TURP patients. Equivalent increases in mean peak flow rate were 8.2 to 12.3 ml/s and 7.3 to 12.8 ml/s for laser and TURP patients, respectively. Mean TRUS volume decreased from 33.9 to 32.9 cc and 29.6 to 26.3 cc for laser and TURP patients, respectively. These data suggest a similar durability of results in patients undergoing laser prostatectomy or TURP.
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